Jubilant IngreviaQ1 FY25

Jubilant Ingrevia Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹588.45P/E: 26.0Market Cap: ₹9.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue.
  • Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target.
  • CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert.
  • Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady.
  • Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in Q3 FY25.
  • New product lines (diketene, food-grade choline bitartrate) showing strong traction and contributing to volume growth.
  • Overall specialty segments reported stable or increasing volumes seasonally, with expectations of volume growth in FY25 compared to FY24.
  • Continued focus on customer centricity and ramping up new plants to sustain growth momentum.

See what Jubilant Ingrevia management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of any current or upcoming fundraising through debt or equity in the transcript.
  • Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals.
  • The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA.
  • No indication from management about plans for incremental debt or equity raising.
  • Focus appears to be on internal funding for expansion and ongoing initiatives.

See what Jubilant Ingrevia management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation.
  • Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand.
  • Significant investment has already been made in the new agrochemical plant.
  • Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years.
  • Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals.
  • Multiple initiatives under "Pinnacle 345" growth roadmap, including investments in high potential product categories and sustainability efforts such as sourcing renewable energy.
  • CDMO business expected to grow with steady investments, targeting 25%-30% year-on-year growth; includes pharma, agro, and semiconductor opportunities.

Track Jubilant Ingrevia — get its next earnings analysis in your feed

How does Jubilant Ingrevia rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisJubilant Ingrevia
Rev 2Mar 1

How does Jubilant Ingrevia rank in Chemicals & Petrochemicals?

Compare Jubilant Ingrevia against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →